Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04884191 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT04884191: Completed Phase 2 study, sponsored by CTI BioPharma.
NCT04884191 is a Phase 2 study that has completed, run by CTI BioPharma. The registered enrollment target is 165 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04884191, a Phase 2 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System \[DIPSS\] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.
Interventions
- DRUG Pacritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2017-07-31 |
| Est. Completion | 2019-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04884191
The ClinicalTrials.gov registry entry for NCT04884191 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pacritinib is the first listed.
NCT04884191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04884191 about?
NCT04884191 is a clinical study titled "Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib". This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System \[DIPSS\] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage se...
What is the current status of trial NCT04884191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2017-07-31. Estimated completion is 2019-09-04.
What interventions are being tested in trial NCT04884191?
The interventions under investigation include: Pacritinib (DRUG).
Who is sponsoring clinical trial NCT04884191?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.